[
  {
    "ts": null,
    "headline": "Is Merck & Co. (MRK) the Low Volatility Stock to Buy According to Billionaire Ken Fisher?",
    "summary": "We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other low volatility stocks to buy according to billionaire Ken Fisher. Billionaire Ken Fisher, a prominent money manager, renowned […]",
    "url": "https://finnhub.io/api/news?id=7e016d6cd464971cac9fa4b855dff43913d12985c14fdeefa245ee40b55e927a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743111397,
      "headline": "Is Merck & Co. (MRK) the Low Volatility Stock to Buy According to Billionaire Ken Fisher?",
      "id": 133505700,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other low volatility stocks to buy according to billionaire Ken Fisher. Billionaire Ken Fisher, a prominent money manager, renowned […]",
      "url": "https://finnhub.io/api/news?id=7e016d6cd464971cac9fa4b855dff43913d12985c14fdeefa245ee40b55e927a"
    }
  },
  {
    "ts": null,
    "headline": "Tracking Cliff Asness' AQR Capital Management 13F Portfolio - Q4 2024 Update",
    "summary": "AQR Capital Management's portfolio grew to $77.63B with top stakes in Apple, Nvidia, Microsoft, Amazon and Alphabet. Read here for a portfolio update.",
    "url": "https://finnhub.io/api/news?id=0f9f76ea1dfc19d71fbc8d6eed19477e768ee0f4440a5d4f249cf95c4ca85f2c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743108470,
      "headline": "Tracking Cliff Asness' AQR Capital Management 13F Portfolio - Q4 2024 Update",
      "id": 133501439,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "AQR Capital Management's portfolio grew to $77.63B with top stakes in Apple, Nvidia, Microsoft, Amazon and Alphabet. Read here for a portfolio update.",
      "url": "https://finnhub.io/api/news?id=0f9f76ea1dfc19d71fbc8d6eed19477e768ee0f4440a5d4f249cf95c4ca85f2c"
    }
  },
  {
    "ts": null,
    "headline": "Merck releases positive data for blockbuster cancer drug",
    "summary": "Merck & Co. (MRK) releases positive phase three data for its injectable-form cancer drug Keytruda. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Market Domination to break down the company's new data. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=88716e3a4f839124dd519a05368f64422516e9717d64929bd0bf2cba14328c52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743106440,
      "headline": "Merck releases positive data for blockbuster cancer drug",
      "id": 133485490,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co. (MRK) releases positive phase three data for its injectable-form cancer drug Keytruda. Yahoo Finance Senior Health Reporter Anjalee Khemlani joins Market Domination to break down the company's new data. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=88716e3a4f839124dd519a05368f64422516e9717d64929bd0bf2cba14328c52"
    }
  },
  {
    "ts": null,
    "headline": "Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares?",
    "summary": "The FDA is due to make an approval decision on injectable Keytruda by mid-September. The move could bolster downtrodden Merck stock.",
    "url": "https://finnhub.io/api/news?id=f85bce47a3e557c3eac69d4df71f72c398b8080ad7603d9ea6914e64c778d356",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743093524,
      "headline": "Merck's Biggest Moneymaker Could Get Even Bigger. But Will It Help Downtrodden Shares?",
      "id": 133481383,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The FDA is due to make an approval decision on injectable Keytruda by mid-September. The move could bolster downtrodden Merck stock.",
      "url": "https://finnhub.io/api/news?id=f85bce47a3e557c3eac69d4df71f72c398b8080ad7603d9ea6914e64c778d356"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA® (pembrolizumab) in Pivotal 3475A-D77 Trial",
    "summary": "RAHWAY, N.J., March 27, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the subcutaneous administration of pembrolizumab, together with berahyaluronidase alfa (MK-3475A; from now on referred to as \"subcutaneous pembrolizumab\"). Berahyaluronidase alfa is a variant of human hyaluronidase developed and manufactured by Alteogen Inc. These results are being presented today a",
    "url": "https://finnhub.io/api/news?id=2793e6902f249d661163bf985060d60316b31281d718ac5e194b0e29dde357f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743087660,
      "headline": "Merck’s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA® (pembrolizumab) in Pivotal 3475A-D77 Trial",
      "id": 133481385,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., March 27, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the subcutaneous administration of pembrolizumab, together with berahyaluronidase alfa (MK-3475A; from now on referred to as \"subcutaneous pembrolizumab\"). Berahyaluronidase alfa is a variant of human hyaluronidase developed and manufactured by Alteogen Inc. These results are being presented today a",
      "url": "https://finnhub.io/api/news?id=2793e6902f249d661163bf985060d60316b31281d718ac5e194b0e29dde357f2"
    }
  },
  {
    "ts": null,
    "headline": "Positive phase III data gives Merck potential boost for blockbuster Keytruda in injection form",
    "summary": "Merck has filed for approval for a new drug that could buoy the bottom line from headwinds in recent months.",
    "url": "https://finnhub.io/api/news?id=9a76b7624f852d4208510bbb16618a6f4ce13ba24923f861b8a982bd6e3888ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743087609,
      "headline": "Positive phase III data gives Merck potential boost for blockbuster Keytruda in injection form",
      "id": 133481387,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck has filed for approval for a new drug that could buoy the bottom line from headwinds in recent months.",
      "url": "https://finnhub.io/api/news?id=9a76b7624f852d4208510bbb16618a6f4ce13ba24923f861b8a982bd6e3888ac"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co (MRK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit",
    "summary": "LOS ANGELES, March 27, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Merck & Co . ...",
    "url": "https://finnhub.io/api/news?id=d2f79ab636b882277c2ea76640838316442dc3420fa7d10b65fbbe55b806736e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743076869,
      "headline": "Merck & Co (MRK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit",
      "id": 133478814,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "LOS ANGELES, March 27, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Merck & Co . ...",
      "url": "https://finnhub.io/api/news?id=d2f79ab636b882277c2ea76640838316442dc3420fa7d10b65fbbe55b806736e"
    }
  },
  {
    "ts": null,
    "headline": "China Expansion Helps Fuel This AI-Powered Cloud Stock In Rough Market",
    "summary": "Boosted by partnerships with Big Pharma and a push into China, Veeva continues to battle to break out in troubled market.",
    "url": "https://finnhub.io/api/news?id=ead1eaea6e1a2d4892467d232ea91ace4a8599318c6737747b154e0a618d69cb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743076834,
      "headline": "China Expansion Helps Fuel This AI-Powered Cloud Stock In Rough Market",
      "id": 133468042,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Boosted by partnerships with Big Pharma and a push into China, Veeva continues to battle to break out in troubled market.",
      "url": "https://finnhub.io/api/news?id=ead1eaea6e1a2d4892467d232ea91ace4a8599318c6737747b154e0a618d69cb"
    }
  },
  {
    "ts": null,
    "headline": "Merck Says FDA PDUFA Date For Subcutaneous Pembrolizumab Set For Sept 23",
    "summary": "Merck & Co Inc: * MERCK: INVESTIGATIONAL SUBCUTANEOUS PEMBROLIZUMAB WITHBERAHYALURONIDASE ALFA SHOWS NONINFERIOR PHARMACOKINETICS VERSUSIV KEYTRUDA IN 3475A-D77 TRIAL *...",
    "url": "https://finnhub.io/api/news?id=f41212b17abb6a6eee9790d98cd987c2bcf88b17111eae4267f165e1aa1eb6c0",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743073203,
      "headline": "Merck Says FDA PDUFA Date For Subcutaneous Pembrolizumab Set For Sept 23",
      "id": 133475582,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck & Co Inc: * MERCK: INVESTIGATIONAL SUBCUTANEOUS PEMBROLIZUMAB WITHBERAHYALURONIDASE ALFA SHOWS NONINFERIOR PHARMACOKINETICS VERSUSIV KEYTRUDA IN 3475A-D77 TRIAL *...",
      "url": "https://finnhub.io/api/news?id=f41212b17abb6a6eee9790d98cd987c2bcf88b17111eae4267f165e1aa1eb6c0"
    }
  },
  {
    "ts": null,
    "headline": "Merck plans to  launch US subcutaneous version of Keytruda on October 1",
    "summary": "Merck & Co saidon Thursday that it plans to launch a subcutaneously injectedversion of its blockbuster cancer immunotherapy Keytruda in theU.S. on October 1, and expects to hit peak adoption rates...",
    "url": "https://finnhub.io/api/news?id=19bd5f91624c20484dc9368ac806521208b623f1a5fc2c66cee16ea7b54a2f86",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743073200,
      "headline": "Merck plans to  launch US subcutaneous version of Keytruda on October 1",
      "id": 133475448,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck & Co saidon Thursday that it plans to launch a subcutaneously injectedversion of its blockbuster cancer immunotherapy Keytruda in theU.S. on October 1, and expects to hit peak adoption rates...",
      "url": "https://finnhub.io/api/news?id=19bd5f91624c20484dc9368ac806521208b623f1a5fc2c66cee16ea7b54a2f86"
    }
  },
  {
    "ts": null,
    "headline": "Class Action Filed Against Merck & Co., Inc. (MRK) - April 14, 2025 Deadline to Join - Contact The Gross Law Firm",
    "summary": "NEW YORK, March 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. . ...",
    "url": "https://finnhub.io/api/news?id=ced82b3cc9d560c18f11eb06a27f5bb8f69d2bd5b3266c16a6e41c3bad55ed42",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743054384,
      "headline": "Class Action Filed Against Merck & Co., Inc. (MRK) - April 14, 2025 Deadline to Join - Contact The Gross Law Firm",
      "id": 133466347,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "NEW YORK, March 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. . ...",
      "url": "https://finnhub.io/api/news?id=ced82b3cc9d560c18f11eb06a27f5bb8f69d2bd5b3266c16a6e41c3bad55ed42"
    }
  },
  {
    "ts": null,
    "headline": "Here is Why Jim Cramer Is Bullish About Merck (MRK)",
    "summary": "We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other stocks that Jim Cramer discussed recently. Jim Cramer, host of Mad Money, expressed his frustration on March 19 about how investors […]",
    "url": "https://finnhub.io/api/news?id=11cdc98ea1d43a7ecf575f7dd1714f5a3309c9064bf4a433447ef62c8c76f01f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743039673,
      "headline": "Here is Why Jim Cramer Is Bullish About Merck (MRK)",
      "id": 133462081,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other stocks that Jim Cramer discussed recently. Jim Cramer, host of Mad Money, expressed his frustration on March 19 about how investors […]",
      "url": "https://finnhub.io/api/news?id=11cdc98ea1d43a7ecf575f7dd1714f5a3309c9064bf4a433447ef62c8c76f01f"
    }
  }
]